

Heart valve disease Committee meeting 17

Date: 18/05/2021

Location: Virtual meeting via Zoom

Minutes: Final

Committee members present:	
Joy Ellery (JE)	(Present for notes 1 – 4)
Madalina Garbi (MG)	(Present for notes 1 – 4)
Marjan Jahangiri (MJ)	(Present for notes 1 – 4)
Muhammad Murad Khan (MMK)	(Present for notes 1 – 4)
Rajesh Kharbanda (RKK)	(Present for notes 1 – 4)
Saul Myerson (SM)	(Present for notes 1 – 4)
Suzannah Power (SP)	(Present for notes 1 – 4)
Phil Smith (PS) (Chair)	(Present for notes 1 – 4)

In attendance:		
Victoria Axe (VA)	Guideline Commissioning Manager, NICE	(Present for notes 1 – 4)
Anne-Louise Clayton	Senior Medical Editor, NICE	(Present for notes 1 – 4)
Amy Crisp (AC)	Senior Project Manager, NGC	(Present for notes 1 – 4)
Nicole Downes (ND)	Systematic Reviewer, NGC	(Present for notes 1 – 4)
Alfredo Mariani (AM)	Health Economist, NGC	(Present for notes 1 – 4)
Benjamin Pearce (BP)	Medical Editor, NICE	(Present for notes 1 – 4)
Eleanor Samarasekera (ES)	Senior Research Fellow, NGC	(Present for notes 1 – 4)
Sharon Swain (SS)	Guideline Lead, NGC	(Present for notes 1 – 4)
David Wonderling (DW)	Head of Health Economics, NGC	(Present for notes 1 – 4)
Apologies:		
Norman Briffa (NB)	Committee member	
Denise Parkin (DP)	Committee member	

1. Welcome and objectives for the meeting

PS welcomed the Committee members and attendees to the seventeenth meeting of

the Heart Valve Disease guideline. The Committee members and attendees introduced themselves.

PS outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The DOI register was made available to PS. PS reviewed the DOI register and deemed that two committee members had DOIs that were in conflict with the agenda topics under discussion at this meeting:

- MG for stress echo, monitoring, and indications for interventions for people with asymptomatic aortic stenosis.
- SM for diagnosis of heart valve disease, MRI for aortic stenosis, MRI for mitral regurgitation, MRI for aortic regurgitation, and pharmacological management without heart failure.

The Chair managed participation and discussion in line with the DOI policy.

The Chair also asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were received for this committee meeting.

3. Discussion

3.1 The team discussed the stakeholder comments with the committee and made edits to the guideline documents.

4. Any other business

None.